CD96 Protein (CD96) (AA 22-503) (His tag)

N° du produit ABIN6253681

Détail du produit

Antigène: CD96

Type de proteíne: Recombinant

Activité biologique: Active

Attributs du protein: AA 22-503

Origine: Humain

Source: HEK-293 Cells

Purification/Conjugué: Cette CD96 protéine est marqué à la His tag.

Séquence: AA 22-503

Attributs du produit: This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 55.4 kDa. The protein migrates as 90-130 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Pureté: >90 % as determined by SDS-PAGE.

niveau d'endotoxine: Less than 1.0 EU per μg by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: PBS, pH 7.4

Conseil sur la manipulation: Please avoid repeated freeze-thaw cycles.

Stock: -20 °C

Détail du antigène

Antigène: CD96

Autre désignation: CD96 (CD96 Produits)

Synonymes: 1700109I12Rik Protein, Tactile Protein, TACTILE Protein, CD96 antigen Protein, CD96 molecule Protein, Cd96 Protein, CD96 Protein

Sujet: The progression of pancreatic cancer (PC) is significantly associated with tumor immune escape, which may be associated with nature killer (NK) cell dysfunction. CD226, CD96, and TIGIT, which share the ligand CD155, play important roles in the regulation of NK cell function. The present study was conducted to investigate the roles of these molecules in NK cells from PC patients. TIGIT and CD96 together with the co-stimulatory receptor CD226 form a pathway that is analogous to the CD28/CTLA-4 pathway, in which shared ligands and differential receptor:ligand affinities fine-tune the immune response. Although the roles of TIGIT and CD96 as immune checkpoint receptors in T cell and natural killer cell biology are just beginning to be uncovered, accumulating data support the targeting of these receptors for improving anti-tumor immune responses. A clear understanding of the immune cell populations regulated by TIGIT and CD96 is key to the design of immunotherapies that target these receptors in combination with other existing immune checkpoint blockade therapies. The dysfunction of CD96 may trigger C syndrome: A syndrome characterized by trigonocephaly, severe mental retardation, hypotonia, variable cardiac defects, redundant skin, and dysmorphic facial features, including upslanted palpebral fissures, epicanthal folds, depressed nasal bridge, and low-set, posteriorly rotated ears.

Poids moléculaire: 55.4 kDa

NCBI Accession: NP_005807